Human papillomavirus and tonsillar and base of tongue cancer

Viruses

Volumn 7, Issue 3, 2015, Pages 1332-1343

  Ramqvist, Torbjörn ^a   Grün, Nathalie ^a   Dalianis, Tina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Base of tongue squamous cell carcinoma cancer; Clinical outcome; Human papillomavirus; Oral HPV prevalence; Tonsillar squamous cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; CD98 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HERMES ANTIGEN; PROTEIN E5; PROTEIN E7; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN;

CANCER RISK; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHROMOSOME 3Q; GENE CONTROL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; IMMUNOHISTOCHEMISTRY; INFECTION PREVENTION; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TONGUE CANCER; TONSIL CANCER; TREATMENT RESPONSE; WART VIRUS; CARCINOMA, SQUAMOUS CELL; CLASSIFICATION; COMPLICATION; ISOLATION AND PURIFICATION; MORTALITY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SURVIVAL ANALYSIS; TONGUE NEOPLASMS; TONSILLAR NEOPLASMS; TREATMENT OUTCOME; VIROLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

CARCINOMA, SQUAMOUS CELL; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SURVIVAL ANALYSIS; TONGUE NEOPLASMS; TONSILLAR NEOPLASMS; TREATMENT OUTCOME;

EID: 84925849797     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7031332     Document Type: Review

References (75)

1. IARC. Human Papillomaviruses; WHO: Lyon, France, 1995; Volume 64.
2. Dahlgren, L.; Dahlstrand, H.M.; Lindquist, D.; Hogmo, A.; Bjornestal, L.; Lindholm, J.; Lundberg, B.; Dalianis, T.; Munck-Wikland, E. Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients. Int. J. Cancer 2004, 112, 1015–1019.
3. Dahlstrand, H.M.; Dalianis, T. Presence and influence of human papillomaviruses (HPV) in tonsillar cancer. Adv. Cancer Res. 2005, 93, 59–89.
4. Gillison, M.L.; Koch, W.M.; Capone, R.B.; Spafford, M.; Westra, W.H.; Wu, L.; Zahurak, M.L.; Daniel, R.W.; Viglione, M.; Symer, D.E. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 2000, 92, 709–720.
5. IARC. Human Papillomaviruses; WHO: Lyon, France, 2007; Volume 90.
6. Marklund, L.; Näsman, A.; Ramqvist, T.; Dalianis, T.; Munck-Wikland, E.; Hammarstedt, L. Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. Cancer Med. 2012, 1, 82–88.
7. Mellin, H.; Friesland, S.; Lewensohn, R.; Dalianis, T.; Munck-Wikland, E. Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival. Int. J. Cancer 2000, 89, 300–304.
8. Attner, P.; Du, J.; Nasman, A.; Hammarstedt, L.; Ramqvist, T.; Lindholm, J.; Marklund, L.; Dalianis, T.; Munck-Wikland, E. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int. J. Cancer 2010, 126, 2879–2884.
9. Lindquist, D.; Romanitan, M.; Hammarstedt, L.; Nasman, A.; Dahlstrand, H.; Lindholm, J.; Onelov, L.; Ramqvist, T.; Ye, W.; Munck-Wikland, E. et al. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of e6 and e7. Mol. Oncol. 2007, 1, 350–355.
10. Braakhuis, B.J.; Visser, O.; Leemans, C.R. Oral and oropharyngeal cancer in the netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral. Oncol. 2009, 45, e85–e89.
11. Chaturvedi, A.K.; Engels, E.A.; Anderson, W.F.; Gillison, M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the united states. J. Clin. Oncol. 2008, 26, 612–619.
12. Chaturvedi, A.K.; Engels, E.A.; Pfeiffer, R.M.; Hernandez, B.Y.; Xiao, W.; Kim, E.; Jiang, B.; Goodman, M.T.; Sibug-Saber, M.; Cozen, W. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J. Clin. Oncol. 2011, 29, 4294–4301.
13. Conway, D.I.; Stockton, D.L.; Warnakulasuriya, K.A.; Ogden, G.; Macpherson, L.M. Incidence of oral and oropharyngeal cancer in united kingdom (1990–1999)—Recent trends and regional variation. Oral. Oncol. 2006, 42, 586–592.
14. Hammarstedt, L.; Dahlstrand, H.; Lindquist, D.; Onelov, L.; Ryott, M.; Luo, J.; Dalianis, T.; Ye, W.; Munck-Wikland, E. The incidence of tonsillar cancer in sweden is increasing. Acta Otolaryngol. 2007, 127, 988–992.
15. Hammarstedt, L.; Lindquist, D.; Dahlstrand, H.; Romanitan, M.; Dahlgren, L.O.; Joneberg, J.; Creson, N.; Lindholm, J.; Ye, W.; Dalianis, T. et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int. J. Cancer 2006, 119, 2620–2623.
16. Marur, S.; D’Souza, G.; Westra, W.H.; Forastiere, A.A. HPV-associated head and neck cancer: A virus-related cancer epidemic. Lancet Oncol. 2010, 11, 781–789.
17. Nasman, A.; Attner, P.; Hammarstedt, L.; Du, J.; Eriksson, M.; Giraud, G.; Ahrlund-Richter, S.; Marklund, L.; Romanitan, M.; Lindquist, D. et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in stockholm, sweden: An epidemic of viral-induced carcinoma? Int. J. Cancer 2009, 124, 150–156.
18. Ramqvist, T.; Dalianis, T. Oropharyngeal cancer epidemic and human papillomavirus. Emerg. Infect. Dis. 2010, 16, 1671–1677.
19. Ramqvist, T.; Dalianis, T. An epidemic of oropharyngeal squamous cell carcinoma (oscc) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res. 2011, 31, 1515–1519.
20. Robinson, K.L.; Macfarlane, G.J. Oropharyngeal cancer incidence and mortality in scotland: Are rates still increasing? Oral. Oncol. 2003, 39, 31–36.
21. Sturgis, E.M.; Cinciripini, P.M. Trends in head and neck cancer incidence in relation to smoking prevalence: An emerging epidemic of human papillomavirus-associated cancers? Cancer 2007, 110, 1429–1435.
22. Tommasino, M. The human papillomavirus family and its role in carcinogenesis. Semin. Cancer Biol. 2014, 26, 13–21.
23. Zur Hausen, H. Papillomavirus infections: A major cause of human cancer. In Infections Causing Human Cancer; Wiley-VCH Verlag: Weinheim, Germary, 2006; pp. 145–243.
24. Dalianis, T. Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (review). Int. J. Oncol. 2014, 44, 1799–1805.
25. IARC. Human papillomaviruses. In Iarc Monographs on the Evaluation of Carcinogenic Risk to Humans. A Review of Human Carcinogens. B. Biological Agents; WHO: Lyon, France, 2011; Volume 100B, pp. 261–301.
26. Du, J.; Nasman, A.; Carlson, J.W.; Ramqvist, T.; Dalianis, T. Prevalence of human papillomavirus (HPV) types in cervical cancer 2003–2008 in stockholm, sweden, before public HPV vaccination. Acta Oncol. 2011, 50, 1215–1219.
27. Oguejiofor, K.K.; Hall, J.S.; Mani, N.; Douglas, C.; Slevin, N.J.; Homer, J.; Hall, G.; West, C.M. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma. Clin. Oncol. 2013, 25, 630–638.
28. Smeets, S.J.; Hesselink, A.T.; Speel, E.J.; Haesevoets, A.; Snijders, P.J.; Pawlita, M.; Meijer, C.J.; Braakhuis, B.J.; Leemans, C.R.; Brakenhoff, R.H. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. J. Cancer 2007, 121, 2465–2472.
29. Ramqvist, T.; Andreasson, K.; Dalianis, T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin. Biol. Ther. 2007, 7, 997–1007.
30. Group, F.I.S. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 2007, 356, 1915–1927.
31. Paavonen, J.; Jenkins, D.; Bosch, F.X.; Naud, P.; Salmeron, J.; Wheeler, C.M.; Chow, S.N.; Apter, D.L.; Kitchener, H.C.; Castellsague, X. et al. Efficacy of a prophylactic adjuvanted bivalent l1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase iii double-blind, randomised controlled trial. Lancet 2007, 369, 2161–2170.
32. Grun, N.; Ahrlund-Richter, A.; Franzen, J.; Mirzaie, L.; Marions, L.; Ramqvist, T.; Dalianis, T. Oral human papillomavirus (HPV) prevalence in youth and cervical HPV prevalence in women attending a youth clinic in sweden, a follow up-study 2013–2014 after gradual introduction of public HPV vaccination. Infect. Dis. 2015, 47, 57–61.
33. Herrero, R.; Quint, W.; Hildesheim, A.; Gonzalez, P.; Struijk, L.; Katki, H.A.; Porras, C.; Schiffman, M.; Rodriguez, A.C.; Solomon, D. et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in costa rica. PLOS ONE 2013, 8, e68329.
34. Antonsson, A.; Cornford, M.; Perry, S.; Davis, M.; Dunne, M.P.; Whiteman, D.C. Prevalence and risk factors for oral HPV infection in young australians. PLOS ONE 2014, 9, e91761.
35. Nordfors, C.; Grun, N.; Haeggblom, L.; Tertipis, N.; Sivars, L.; Mattebo, M.; Larsson, M.; Haggstrom-Nordin, E.; Tyden, T.; Ramqvist, T. et al. Oral human papillomavirus prevalence in high school students of one municipality in sweden. Scand. J. Infect. Dis. 2013, 45, 878–881.
36. Licitra, L.; Bernier, J.; Grandi, C.; Merlano, M.; Bruzzi, P.; Lefebvre, J.L. Cancer of the oropharynx. Crit. Rev. Oncol. Hematol. 2002, 41, 107–122.
37. Ang, K.K.; Harris, J.; Wheeler, R.; Weber, R.; Rosenthal, D.I.; Nguyen-Tan, P.F.; Westra, W.H.; Chung, C.H.; Jordan, R.C.; Lu, C. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 2010, 363, 24–35.
38. Koskinen, W.J.; Chen, R.W.; Leivo, I.; Makitie, A.; Back, L.; Kontio, R.; Suuronen, R.; Lindqvist, C.; Auvinen, E.; Molijn, A. et al. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int. J. Cancer 2003, 107, 401–406.
39. Mellin Dahlstrand, H.; Lindquist, D.; Bjornestal, L.; Ohlsson, A.; Dalianis, T.; Munck-Wikland, E.; Elmberger, G. P16(ink4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res. 2005, 25, 4375–4383.
40. Mellin, H.; Dahlgren, L.; Munck-Wikland, E.; Lindholm, J.; Rabbani, H.; Kalantari, M.; Dalianis, T. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int. J. Cancer 2002, 102, 152–158.
41. Dahlgren, L.; Mellin, H.; Wangsa, D.; Heselmeyer-Haddad, K.; Bjornestal, L.; Lindholm, J.; Munck-Wikland, E.; Auer, G.; Ried, T.; Dalianis, T. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int. J. Cancer 2003, 107, 244–249.
42. Mellin, H.; Friesland, S.; Auer, G.; Dalianis, T.; Munck-Wikland, E. Human papillomavirus and DNA ploidy in tonsillar cancer—Correlation to prognosis. Anticancer Res. 2003, 23, 2821–2828.
43. Clavel, C.; Masure, M.; Bory, J.P.; Putaud, I.; Mangeonjean, C.; Lorenzato, M.; Gabriel, R.; Quereux, C.; Birembaut, P. Hybrid capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: A preliminary study on 1518 women. Br. J. Cancer 1999, 80, 1306–1311.
44. de Roda Husman, A.M.; Walboomers, J.M.; van den Brule, A.J.; Meijer, C.J.; Snijders, P.J. The use of general primers gp5 and gp6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 1995, 76, 1057–1062.
45. Gravitt, P.E.; Peyton, C.L.; Apple, R.J.; Wheeler, C.M. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J. Clin. Microbiol. 1998, 36, 3020–3027.
46. Schmitt, M.; Bravo, I.G.; Snijders, P.J.; Gissmann, L.; Pawlita, M.; Waterboer, T. Bead-based multiplex genotyping of human papillomaviruses. J. Clin. Microbiol. 2006, 44, 504–512.
47. Tieben, L.M.; ter Schegget, J.; Minnaar, R.P.; Bouwes Bavinck, J.N.; Berkhout, R.J.; Vermeer, B.J.; Jebbink, M.F.; Smits, H.L. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J. Virol. Methods 1993, 42, 265–279.
48. van den Brule, A.J.; Pol, R.; Fransen-Daalmeijer, N.; Schouls, L.M.; Meijer, C.J.; Snijders, P.J. Gp5+/6+ pcr followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 2002, 40, 779–787.
49. Nasman, A.; Nordfors, C.; Holzhauser, S.; Vlastos, A.; Tertipis, N.; Hammar, U.; Hammarstedt-Nordenvall, L.; Marklund, L.; Munck-Wikland, E.; Ramqvist, T. et al. Incidence of human papillomavirus positive tonsillar and base of tongue carcinoma: A stabilisation of an epidemic of viral induced carcinoma? Eur. J. Cancer 2015, 51, 55–61.
50. Garnaes, E.; Kiss, K.; Andersen, L.; Therkildsen, M.H.; Franzmann, M.B.; Filtenborg-Barnkob, B.; Hoegdall, E.; Krenk, L.; Josiassen, M.; Lajer, C.B. et al. A high and increasing HPV prevalence in tonsillar cancers in eastern denmark, 2000–2010: The largest registry-based study to date. Int. J. Cancer 2014, 136, 2196–2203.
51. Anaya-Saavedra, G.; Ramirez-Amador, V.; Irigoyen-Camacho, M.E.; Garcia-Cuellar, C.M.; Guido-Jimenez, M.; Mendez-Martinez, R.; Garcia-Carranca, A. High association of human papillomavirus infection with oral cancer: A case-control study. Arch. Med. Res. 2008, 39, 189–197.
52. D’Souza, G.; Agrawal, Y.; Halpern, J.; Bodison, S.; Gillison, M.L. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J. Infect. Dis. 2009, 199, 1263–1269.
53. Syrjanen, S.; Puranen, M. Human papillomavirus infections in children: The potential role of maternal transmission. Crit. Rev. Oral Biol. Med. 2000, 11, 259–274.
54. Lindquist, D.; Ahrlund-Richter, A.; Tarjan, M.; Tot, T.; Dalianis, T. Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res. 2012, 32, 153–161.
55. Lindquist, D.; Nasman, A.; Tarjan, M.; Henriksson, R.; Tot, T.; Dalianis, T.; Hedman, H. Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer. Br. J. Cancer 2014, 110, 1793–1800.
56. Nasman, A.; Andersson, E.; Marklund, L.; Tertipis, N.; Hammarstedt-Nordenvall, L.; Attner, P.; Nyberg, T.; Masucci, G.V.; Munck-Wikland, E.; Ramqvist, T. et al. HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome. PLOS ONE 2013, 8, e77025.
57. Nasman, A.; Andersson, E.; Nordfors, C.; Grun, N.; Johansson, H.; Munck-Wikland, E.; Massucci, G.; Dalianis, T.; Ramqvist, T. MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int. J. Cancer 2013, 132, 72–81.
58. Nasman, A.; Nordfors, C.; Grun, N.; Munck-Wikland, E.; Ramqvist, T.; Marklund, L.; Lindquist, D.; Dalianis, T. Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival. Cancer Med. 2013, 2, 507–518.
59. Rietbergen, M.M.; Martens-de Kemp, S.R.; Bloemena, E.; Witte, B.I.; Brink, A.; Baatenburg de Jong, R.J.; Leemans, C.R.; Braakhuis, B.J.; Brakenhoff, R.H. Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur. J. Cancer 2014, 50, 765–773.
60. Tertipis, N.; Haeggblom, L.; Grün, N.; Nordfors, C.; Näsman, A.; Dalianis, T.; Ramqvist, T. Reduced expression of the antigen processing machinery components TAP2, LMP2 and LMP7 in tonsillar and base of tongue cancer and implications for clinical outcome. Transl. Oncol. 2015, 8, 10–17.
61. Tertipis, N.; Haeggblom, L.; Nordfors, C.; Grun, N.; Nasman, A.; Vlastos, A.; Dalianis, T.; Ramqvist, T. Correlation of lmp10 expression and clinical outcome in human papillomavirus (HPV) positive and HPV-negative tonsillar and base of tongue cancer. PLOS ONE 2014, 9, e95624.
62. Tertipis, N.; Villabona, L.; Nordfors, C.; Nasman, A.; Ramqvist, T.; Vlastos, A.; Masucci, G.; Dalianis, T. Hla-a*02 in relation to outcome in human papillomavirus positive tonsillar and base of tongue cancer. Anticancer Res. 2014, 34, 2369–2375.
63. Nasman, A.; Romanitan, M.; Nordfors, C.; Grun, N.; Johansson, H.; Hammarstedt, L.; Marklund, L.; Munck-Wikland, E.; Dalianis, T.; Ramqvist, T. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLOS ONE 2012, 7, e38711.
64. Nordfors, C.; Grün, N.; Tertipis, N.; Ährlund-Richter, A.; Haeggblom, L.; Sivars, L.; Du, J.; Nyberg, T.; Marklund, L.; Munck-Wikland, E. et al. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur. J. Cancer 2013, 49, 2522–2530.
65. Hui, A.B.; Lin, A.; Xu, W.; Waldron, L.; Perez-Ordonez, B.; Weinreb, I.; Shi, W.; Bruce, J.; Huang, S.H.; O’Sullivan, B. et al. Potentially prognostic mirnas in HPV-associated oropharyngeal carcinoma. Clin. Cancer Res. 2013, 19, 2154–2162.
66. Lajer, C.B.; Nielsen, F.C.; Friis-Hansen, L.; Norrild, B.; Borup, R.; Garnaes, E.; Rossing, M.; Specht, L.; Therkildsen, M.H.; Nauntofte, B. et al. Different mirna signatures of oral and pharyngeal squamous cell carcinomas: A prospective translational study. Br. J. Cancer 2011, 104, 830–840.
67. Miller, J.F. Influence of thymectomy on tumor induction by polyoma virus in C57BL mice. Proc. Soc. Exp. Biol. Med. 1964, 116, 323–327.
68. Du, J.; Nordfors, C.; Ahrlund-Richter, A.; Sobkowiak, M.; Romanitan, M.; Nasman, A.; Andersson, S.; Ramqvist, T.; Dalianis, T. Prevalence of oral human papillomavirus infection among youth, Sweden. Emerg. Infect. Dis. 2012, 18, 1468–1471.
69. Kreimer, A.R.; Bhatia, R.K.; Messeguer, A.L.; Gonzalez, P.; Herrero, R.; Giuliano, A.R. Oral human papillomavirus in healthy individuals: A systematic review of the literature. Sex. Transm. Dis. 2010, 37, 386–391.
70. Rautava, J.; Syrjanen, S. Human papillomavirus infections in the oral mucosa. J. Am. Dent. Assoc. 2011, 142, 905–914.
71. Steinau, M.; Hariri, S.; Gillison, M.L.; Broutian, T.R.; Dunne, E.F.; Tong, Z.Y.; Markowitz, L.E.; Unger, E.R. Prevalence of cervical and oral human papillomavirus infections among US women. J. Infect. Dis. 2014, 209, 1739–1743.
72. Nordfors, C.; Vlastos, A.; Du, J.; Ahrlund-Richter, A.; Tertipis, N.; Grun, N.; Romanitan, M.; Haeggblom, L.; Roosaar, A.; Dahllof, G. et al. Human papillomavirus prevalence is high in oral samples of patients with tonsillar and base of tongue cancer. Oral Oncol. 2014, 50, 491–497.
73. D’Souza, G.; Kreimer, A.R.; Viscidi, R.; Pawlita, M.; Fakhry, C.; Koch, W.M.; Westra, W.H.; Gillison, M.L. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 2007, 356, 1944–1956.
74. Lang Kuhs, K.A.; Anantharaman, D.; Waterboer, T.; Johansson, M.; Brennan, P.; Michel, A.; Willhauck-Fleckenstein, M.; Purdue, M.P.; Holcatova, I.; Ahrens, W. Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: A Pooled Analysis. Cancer Epidemiol. Biomark. Prev. 2015, doi:10.1158/1055-9965.EPI-14-1217.
75. Fakhry, C.; Rosenthal, B.T.; Clark, D.P.; Gillison, M.L. Associations between oral HPV16 infection and cytopathology: Evaluation of an oropharyngeal “pap-test equivalent” in high-risk populations. Cancer Prev. Res. 2011, 4, 1378–1384.